Represents net earnings attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as ...
The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...
James analyst Gary Nachman maintained an Outperform rating on AbbVie stock (NYSE:ABBV) with a $218.00 price target. The ...
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...
Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the ...
The U.S. surgeon general advised earlier this month that alcohol is a leading preventable cause of cancer, presenting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback